查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995295

氣喘治療市場：2026-2032年全球市場預測（依產品類型、藥物類別、給藥途徑、最終用戶及通路分類）

Asthma Therapeutics Market by Product Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，氣喘治療市場價值將達到 282.6 億美元，到 2026 年將成長至 298.1 億美元，到 2032 年將達到 420.7 億美元，複合年成長率為 5.84%。

主要市場統計數據
基準年 2025 282.6億美元
預計年份：2026年 298.1億美元
預測年份 2032 420.7億美元
複合年成長率 (%) 5.84%

本文簡要概述了正在重塑氣喘藥物和患者照護的臨床、監管和商業交叉領域。

氣喘治療格局正在發生變革，在臨床創新、醫療設備進步和醫療系統壓力三者共同推動下，各年齡層患者的治療模式正在重塑。生物製藥的進步改變了重度氣喘和控制不佳氣喘的治療模式，而吸入器和霧化器技術的不斷改進也持續影響著常規治療。同時，保險公司和醫療服務提供者要求在真實臨床環境中提供更清晰的療效和成本效益證據，這迫使製藥公司重新評估其商業化和實證策略。

詳細檢視生物製藥和醫療設備的融合、支付方的需求以及監管演變如何全面改變氣喘治療及其商業化。

氣喘治療領域正經歷著一場變革性的轉變，其驅動力包括專業化、設備整合、醫療保險監管以及數位科技的應用。針對特定免疫路徑的生物製藥正從小眾應用領域走向重症氣喘治療的核心地位，迫使醫療團隊採用精準醫療方法，依賴生物標記檢測和專科轉診網路。同時，吸入器和霧化器技術的進步提高了劑量控制和使用便利性，結合病患教育，有助於提高病患的長期用藥依從性，並減少其前往急診就診的次數。

對 2025 年美國關稅環境及其對製造選擇、供應韌性和商業策略的下游影響進行全面分析。

美國在2025年實施的新關稅和貿易措施正促使整個氣喘治療生態系統進行策略性重新評估，其累積影響因產品複雜性和供應鏈依賴程度而異。依賴進口零件、專用添加劑或成品醫療設備的公司，其利潤率正因投入成本飆升而受到擠壓，並被迫與供應商重新談判合約。生物製藥製造商尤其脆弱，因為它們通常依賴複雜的高價值價值鍊和低溫運輸物流，而生產連續性和品管至關重要，且難以輕易搬遷工廠。

詳細的細分分析涵蓋產品類型、藥物類別、分銷管道、給藥途徑和最終用戶細分，為策略定位提供指南。

精準的細分觀點對於理解臨床價值和商業性機會在產品類型、給藥途徑、通路、藥物分類和終端用戶群體中的交匯點至關重要。產品類型細分將生物製藥分為吸入劑、霧化器和口服藥物。在生物製藥領域，重點在於針對嗜酸性粒細胞和過敏表現型的抗體療法，例如抗IgE和抗IL-5製劑。另一方面，吸入劑又分為乾粉吸入器、定量吸入器和緩霧吸入器，每種吸入器都有不同的性能特徵，並對用藥依從性產生不同的影響。霧化器進一步細分為噴射霧化器、篩孔式噴霧器和超音波霧化器，其易用性、粒徑控制和便攜性會影響臨床應用。口服藥物包括白三烯調節劑、口服類固醇和茶鹼，它們根據病情嚴重程度、合併症情況和耐受性佔據特定的細分市場。

美洲、歐洲、中東和非洲以及亞太市場准入、監管複雜性和採用趨勢的區域資訊。

區域趨勢影響產品開發、監管策略和商業化重點，美洲、歐洲、中東和非洲以及亞太地區都面臨獨特的機會和挑戰。在美洲，先進的專科醫療網路和生物製藥的廣泛應用促進了重度氣喘治療藥物的快速普及，但支付方日益成熟的監管策略和成本控制壓力要求提供強力的衛生經濟學證據和策略性合約協議。因此，優先考慮美洲市場的製造商往往更注重療效數據、與專科藥房的合作以及能夠減輕患者行政負擔和提高用藥依從性的患者支持模式。

概述影響產品差異化和市場進入的創新者、醫療設備專家、學名藥供應商和製造合作夥伴的策略競爭格局。

氣喘治療領域的競爭動態呈現出創新生物製藥開發商、傳統吸入器和霧化器製造商、學名藥和口服藥物供應商以及新興醫療設備技術參與企業之間互補作用的態勢。專注於單株抗體的創新公司正透過基於生物標記的適應症、生命週期策略以及針對特定表現型患者群體的擴展適應症來實現差異化。這些公司也正在投資伴隨診斷和專業通路，以最佳化患者選擇並提高用藥依從性。

製造商要建立競爭優勢，需要應對以下具體且可操作的策略挑戰：協調臨床證據、與醫療設備整合、供應鏈彈性以及市場進入。

產業領導企業應採取一系列切實可行的策略，將臨床價值、營運韌性和商業性靈活性結合在一起。首先，應優先產生包含真實世界數據和病患報告結局（HRO）在內的證據，而不僅限於隨機對照試驗。這將有助於在與支付方談判時增強價值提案，並鼓勵臨床醫生在日常實踐中採用療效驗證。其次，應在研發早期階段整合醫療設備和數位化能力，建構捆綁式服務模式，進而提高病患依從性，提供可操作的病患數據，並確立高階市場定位。

採用嚴謹的混合方法研究途徑，結合對臨床專家的訪談、二手文獻的整合、供應鏈映射和情境分析，以獲得可靠的見解。

本分析整合了第一手和第二手調查數據，為策略決策提供可靠且可驗證的檢驗基礎。第一手調查包括與呼吸醫學和過敏領域的關鍵意見領袖（KOL）進行結構化討論，與各治療領域和醫療設備細分市場的商業高管進行訪談，以及與負責人和支付方代表進行討論，以了解報銷重點和合約趨勢。這些工作獲得了關於臨床醫生偏好、影響患者依從性的因素以及商業性決策框架的定性見解。

執行摘要強調了整合臨床證據、醫療設備創新、有韌性的供應鏈以及區域最佳化准入策略的必要性。

整體而言，氣喘治療領域蘊藏著一系列複雜但又充滿機會的局面，而這些機會取決於臨床創新與切實可行的商業和營運策略的契合度。生物製藥正在重新定義重症患者的治療，而醫療設備和數位技術的進步則提高了患者的用藥依從性，並支持了新的基於價值的模式。然而，諸如支付方審查和貿易相關關稅變化等外部壓力，要求我們在循證醫學證據的獲取、供應鏈設計和定價策略方面做出相應的調整。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：氣喘治療市場：依產品類型分類

  • 生物製藥
    • 抗IgE
    • 抗IL-5
  • 吸入器
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 緩霧吸入器
  • 噴霧器
    • 噴射式霧化器
    • 篩孔式噴霧器
    • 超音波霧化器
  • 口服藥物
    • 白三烯拮抗劑
    • 口服類固醇
    • 茶鹼

第9章：氣喘治療市場：依藥物類別分類

  • BETA-激動劑
  • 聯合治療
  • 吸入性皮質類固醇
  • 白三烯調節劑
  • 單株抗體

第10章：氣喘治療市場：依給藥途徑分類

  • 吸入
    • 氣霧劑
    • 粉末
  • 口服
    • 糖漿
    • 藥片
  • 腸外
    • 靜脈
    • 皮下

第11章：氣喘治療市場：依最終用戶分類

  • 成人版
  • 老年人
    • 65-74歲
    • 75歲或以上
  • 兒童
    • 0-5歲
    • 6-12歲

第12章：氣喘治療市場：依通路分類

  • 診所
    • 居家醫療設施
    • 門診部
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：氣喘治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章氣喘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：氣喘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國氣喘治療市場

第17章：中國氣喘治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Sumitomo Pharma Company Limited
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market was valued at USD 28.26 billion in 2025 and is projected to grow to USD 29.81 billion in 2026, with a CAGR of 5.84%, reaching USD 42.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.26 billion
Estimated Year [2026] USD 29.81 billion
Forecast Year [2032] USD 42.07 billion
CAGR (%) 5.84%

A concise framing of the converging clinical, regulatory, and commercial forces reshaping asthma therapeutics and patient care pathways

The asthma therapeutics environment is entering a phase where clinical innovation, device evolution, and health system pressures converge to redefine care delivery for patients across age groups. Advances in biologic therapies have shifted treatment paradigms for severe and uncontrolled asthma, while incremental improvements in inhaler and nebulizer technology continue to shape everyday management. At the same time, payers and providers are demanding clearer evidence of real-world effectiveness and cost utility, prompting manufacturers to rethink commercialization and evidence-generation strategies.

As a result, stakeholders must navigate a landscape that balances scientific breakthroughs with operational realities. Regulatory pathways are adapting to accommodate novel biologic modalities and combination products, and supply chains are adjusting to geopolitical and trade dynamics that affect component sourcing and manufacturing footprints. Clinicians and caregivers now expect integrated solutions that couple therapeutics with adherence-enhancing devices and digital monitoring, which in turn forces manufacturers to develop cross-functional capabilities in product development, data analytics, and patient support programs.

This introduction frames the core dynamics influencing therapy selection, device adoption, and stakeholder behavior. It clarifies how the interplay between innovation, reimbursement, and provider workflows will determine competitive advantage, and sets the stage for deeper analysis of transformative shifts, tariff impacts, segmentation insights, and regional considerations included in this report.

Detailed exploration of how biologics, device convergence, payer demands, and regulatory evolution are collectively transforming asthma care and commercialization

The landscape for asthma therapeutics is undergoing transformative shifts driven by therapeutic specialization, device integration, payer scrutiny, and digital augmentation. Biologic therapies targeting specific immunological pathways have moved from niche applications to central roles in the management of severe asthma, compelling care teams to adopt precision medicine approaches that rely on biomarker testing and specialist referral networks. Concurrently, inhaler and nebulizer technologies have improved dose delivery and usability, encouraging longer-term adherence and reducing acute care episodes when paired with patient education initiatives.

In parallel, payers and health systems are demanding stronger value narratives, creating pressure to demonstrate outcomes beyond traditional clinical endpoints. This has accelerated the use of real-world evidence and health economics analyses as core components of market access strategies. Moreover, device-therapy convergence is fostering new commercial models where drug-device combinations and digital adherence platforms become differentiators. Manufacturers that integrate inhalation devices with connected monitoring tools stand to improve clinical outcomes while creating new revenue streams through service offerings.

Finally, regulatory agencies are recalibrating approval and post-market surveillance expectations to match the complexity of combination products and biologics. This regulatory evolution, combined with an emphasis on patient-centric care, is reshaping commercial timelines and clinical development approaches. The net effect is a market that rewards cross-disciplinary innovation, collaborative evidence generation, and nimble commercialization strategies.

Comprehensive analysis of the United States 2025 tariff landscape and its downstream effects on manufacturing choices, supply resilience, and commercial strategies

The introduction of new tariffs and trade measures in the United States in 2025 has prompted a strategic reassessment across the asthma therapeutics ecosystem, with cumulative impacts that vary by product complexity and supply chain dependence. Companies that rely on imported components, specialized excipients, or finished devices have experienced escalated input costs that compress margins and prompt renegotiation of supplier contracts. Manufacturers of biologics, which often depend on complex, high-value supply chains and cold-chain logistics, face particular exposure because production continuity and quality control are critical and not easily relocated.

On the other hand, device-focused producers have had incentives to accelerate onshoring or diversify component sourcing to mitigate tariff-driven cost volatility. This trend has driven increased investment in domestic manufacturing capacity, contract development and manufacturing organization partnerships, and process automation to reduce labor intensity. Payers and procurement teams have responded by tightening formulary criteria and intensifying cost-containment negotiations, which pressures manufacturers to present stronger evidence of comparative effectiveness and to consider innovative pricing arrangements.

Trade measures have also affected timelines for regulatory submissions and launch sequencing in ways that favor companies with vertically integrated supply chains or robust contingency planning. As a result, strategic responses have included accelerating local production, redesigning packaging and component sourcing to avoid tariff classifications, and pursuing strategic alliances to share manufacturing risk. These approaches help preserve competitive positioning while maintaining continuity of supply for clinicians and patients.

In-depth segmentation synthesis describing product types, drug classes, distribution channels, routes of administration, and end-user cohorts to guide strategic positioning

A precise segmentation lens is essential to understand where clinical value and commercial opportunity intersect across product types, administration routes, distribution pathways, drug classes, and end-user cohorts. Product type segmentation differentiates Biologics from Inhalers, Nebulizers, and Oral Drugs; within Biologics the focus is on antibody therapies such as anti-IgE and anti-IL-5 agents that address eosinophilic and allergic phenotypes, while Inhalers are parsed into Dry Powder Inhalers, Metered Dose Inhalers, and Soft Mist Inhalers, each offering distinct performance characteristics and adherence implications. Nebulizers are subdivided into Jet Nebulizers, Mesh Nebulizers, and Ultrasonic Nebulizers, with usability, particle size control, and portability shaping clinical adoption. Oral Drugs encompass Leukotriene Modifiers, Oral Corticosteroids, and Theophylline, which occupy specific niches based on severity, comorbidity profiles, and tolerability considerations.

Drug class segmentation further clarifies therapy selection drivers by distinguishing Beta Agonists, Combination Therapies, Inhaled Corticosteroids, Leukotriene Modifiers, and Monoclonal Antibodies; each class aligns with particular disease severities and guideline recommendations, influencing prescribing patterns and formulary placement. Distribution channel segmentation highlights variations in access and patient experience across Clinics, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and the Clinics category includes Home Care Settings and Outpatient Clinics where administration models and reimbursement pathways differ substantially. Route of administration segmentation captures the clinical and logistical trade-offs among Inhalation, Oral, and Parenteral routes; inhalation itself breaks into Aerosol and Powder formats, oral presentations include Syrup Form and Tablet Form, and parenteral delivery is separated into Intravenous and Subcutaneous approaches that affect clinician involvement, monitoring requirements, and patient preference.

End-user segmentation frames demographic-driven demand across Adult, Geriatric, and Pediatric populations; the Geriatric cohort is further divided into 65-74 Years and 75 Plus Years to reflect functional and polypharmacy considerations, while the Pediatric cohort is split into 0-5 Years and 6-12 Years to account for differences in device suitability, dosing constraints, and caregiver support needs. Taken together, these segmentation perspectives enable a nuanced view of product positioning, clinical trial design, reimbursement strategy, and go-to-market execution that aligns with real-world treatment pathways and stakeholder expectations.

Regional intelligence on access, regulatory complexity, and adoption dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape priorities for product development, regulatory strategy, and commercialization, with distinct opportunities and constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced specialty care networks and widespread availability of biologic therapies support rapid adoption for severe asthma, yet payer sophistication and cost-containment pressures require robust health economic evidence and strategic contracting. As a result, manufacturers prioritizing the Americas tend to emphasize outcomes data, specialty pharmacy partnerships, and patient support models that reduce administrative friction and improve adherence.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer systems necessitate tailored market access plans that account for national HTA processes, procurement frameworks, and differing reimbursement criteria. Manufacturers operating across these markets often deploy regional clinical registries and real-world evidence programs to demonstrate value in local contexts, while also investing in pricing strategies adaptable to tendering and reference pricing mechanisms. Capacity constraints in parts of the region can create demand for more robust distribution partnerships and training programs to ensure proper device handling and administration.

The Asia-Pacific region presents a multifaceted picture where rapid healthcare modernization coexists with variable infrastructure and access. In certain markets, high-volume generics producers and a growing biotech sector drive intense competition, while other markets show rising demand for advanced therapies as diagnostic capabilities and specialty care expand. Manufacturers targeting Asia-Pacific frequently balance centralized clinical development with localized regulatory engagement, and they explore tiered product offerings and regional manufacturing hubs to manage cost and improve lead times. Across all regions, localized patient engagement and clinician education remain central to successful adoption.

Strategic competitive overview of innovators, device specialists, generic suppliers, and manufacturing partners shaping product differentiation and market entry

Competitive dynamics in asthma therapeutics are characterized by complementary roles played by innovative biologic developers, legacy inhaler and nebulizer manufacturers, generic and oral therapy suppliers, and emerging device-tech entrants. Innovator companies that specialize in monoclonal antibodies are driving differentiation through biomarker-driven indications, lifecycle strategies, and label expansions into phenotype-specific populations. These firms also invest in companion diagnostics and specialty distribution pathways to optimize patient selection and adherence.

Device manufacturers continue to compete on deliverability, user ergonomics, and integration with digital adherence platforms, forging partnerships with pharmaceutical companies to offer differentiated drug-device combinations. Generic players and manufacturers of oral therapies focus on cost-effectiveness and wide availability, frequently leveraging scale manufacturing and distribution networks to serve primary-care channels. Meanwhile, contract development and manufacturing organizations and device component suppliers are crucial enablers, providing capacity and technical expertise that influence speed to market and the feasibility of onshoring initiatives.

Collectively, company strategies emphasize vertical integration where feasible, strategic partnerships to complement core capabilities, and targeted acquisition to secure device know-how or biologic pipelines. Organizations that combine clinical innovation with strong commercial execution, evidence generation, and supply chain resilience are better positioned to navigate payer scrutiny and to capitalize on evolving clinical guidelines and patient expectations.

Actionable strategic imperatives for manufacturers to align clinical evidence, device integration, supply resilience, and market access for competitive advantage

Industry leaders should adopt a set of pragmatic, actionable strategies that align clinical value with operational resilience and commercial agility. First, prioritize evidence generation that extends beyond randomized trials to include real-world data and patient-reported outcomes; this will strengthen value propositions in payer negotiations and support uptake among clinicians who require proof of effectiveness in routine care. Second, integrate device and digital capabilities early in development to enhance adherence, provide actionable patient data, and create bundled service models that can command premium positioning.

Third, optimize supply chains through geographic diversification, strategic contract manufacturing partnerships, and selective onshoring where tariff exposure or logistics risk is unacceptable. By redesigning sourcing and manufacturing footprints now, companies can reduce vulnerability to trade volatility and preserve launch timelines. Fourth, tailor market access strategies to regional regulatory and reimbursement environments by investing in health economics, outcomes research, and local stakeholder engagement; this ensures that pricing and contracting reflect regional payer priorities and clinical practice.

Finally, pursue targeted collaborations-whether co-development, licensing, or commercial alliances-to access complementary capabilities in biologics, device engineering, or digital health. Such partnerships enable faster market entry, share development risk, and expand therapeutic ecosystems. Executing these recommendations will require cross-functional governance, clear KPIs, and staged investment to align R&D, commercial, and manufacturing objectives with evolving market realities.

Rigorous mixed-methods research approach combining clinical expert interviews, secondary literature synthesis, supply chain mapping, and scenario analysis for robust insights

This analysis synthesizes primary and secondary research disciplines to provide a robust and verifiable evidence base for strategic decisions. Primary research included structured consultations with clinical key opinion leaders in pulmonology and allergy, interviews with commercial executives across therapy and device segments, and discussions with procurement and payer representatives to capture reimbursement priorities and contracting trends. These engagements informed qualitative insights into clinician preferences, patient adherence drivers, and commercial decision-making frameworks.

Secondary research incorporated a comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, and industry publications that describe therapeutic mechanisms, device performance characteristics, and safety considerations. Supply chain mapping and tariff classification analysis were used to identify points of vulnerability and to assess likely mitigation strategies. Triangulation of primary and secondary findings ensured consistency across clinical, commercial, and operational dimensions.

Analytical methods included comparative product positioning analysis, scenario planning for tariff and supply chain disruptions, and segmentation-driven assessment to align product attributes with end-user and distribution channel needs. Quality control measures included cross-validation of interview findings, source verification of regulatory and clinical references, and iterative expert review to refine conclusions. Together, these methods produce a defensible and actionable set of insights for stakeholders planning product development, market access, or strategic investment.

Executive synthesis emphasizing the need for integrated clinical evidence, device innovation, resilient supply chains, and regionally tailored access strategies

In sum, the asthma therapeutics arena presents a complex but navigable set of opportunities that hinge on aligning clinical innovation with pragmatic commercial and operational strategies. Biologic therapies have redefined care for severe phenotypes, while device and digital advancements are improving adherence and supporting new value-based models. However, external pressures such as payer scrutiny and trade-related tariff shifts require adaptive responses in evidence generation, supply chain design, and pricing strategies.

Successful stakeholders will be those who can integrate cross-disciplinary capabilities: developing robust real-world evidence programs, designing user-centric devices, and building resilient manufacturing footprints. Investments in partnerships-whether with device engineers, contract manufacturers, or regional distributors-will accelerate market entry and reduce execution risk. Moreover, tailoring strategies to regional regulatory and reimbursement landscapes will enhance access and commercial performance in diverse markets.

This conclusion underscores the imperative for coordinated action across R&D, commercial, and operations teams to translate scientific advances into sustainable patient impact and commercial returns. Organizations that adopt a proactive stance toward evidence, integration, and resilience will be best positioned to lead in the evolving asthma therapeutics ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Anti-Ige
    • 8.1.2. Anti-Il5
  • 8.2. Inhalers
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Metered Dose Inhalers
    • 8.2.3. Soft Mist Inhalers
  • 8.3. Nebulizers
    • 8.3.1. Jet Nebulizers
    • 8.3.2. Mesh Nebulizers
    • 8.3.3. Ultrasonic Nebulizers
  • 8.4. Oral Drugs
    • 8.4.1. Leukotriene Modifiers
    • 8.4.2. Oral Corticosteroids
    • 8.4.3. Theophylline

9. Asthma Therapeutics Market, by Drug Class

  • 9.1. Beta Agonists
  • 9.2. Combination Therapies
  • 9.3. Inhaled Corticosteroids
  • 9.4. Leukotriene Modifiers
  • 9.5. Monoclonal Antibodies

10. Asthma Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Aerosol
    • 10.1.2. Powder
  • 10.2. Oral
    • 10.2.1. Syrup Form
    • 10.2.2. Tablet Form
  • 10.3. Parenteral
    • 10.3.1. Intravenous
    • 10.3.2. Subcutaneous

11. Asthma Therapeutics Market, by End User

  • 11.1. Adult
  • 11.2. Geriatric
    • 11.2.1. 65-74 Years
    • 11.2.2. 75 Plus Years
  • 11.3. Pediatric
    • 11.3.1. 0-5 Years
    • 11.3.2. 6-12 Years

12. Asthma Therapeutics Market, by Distribution Channel

  • 12.1. Clinics
    • 12.1.1. Home Care Settings
    • 12.1.2. Outpatient Clinics
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Asthma Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Asthma Therapeutics Market

17. China Asthma Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Chiesi Farmaceutici S.p.A.
  • 18.9. Cipla Limited
  • 18.10. Eli Lilly and Company
  • 18.11. GlaxoSmithKline plc
  • 18.12. Johnson & Johnson
  • 18.13. Novartis AG
  • 18.14. Sanofi S.A.
  • 18.15. Sumitomo Pharma Company Limited
  • 18.16. Sunovion Pharmaceuticals Inc.
  • 18.17. Takeda Pharmaceutical Company Limited
  • 18.18. Teva Pharmaceutical Industries Limited
  • 18.19. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 298. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 300. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 302. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 303. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS ASTHMA THERAPEUTICS MARKET SIZE,